|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Diabetic Neuropathic Pain - Market Success is Not Limited to Pregabalin
Datamonitor, April 2004, Pages: 133
With millions of diabetes patients suffering from neuropathic pain worldwide and no treatments yet approved for this indication in the US, the diabetic neuropathic pain (DNP) market is set for some dramatic changes.
Key market events in the next few years include the launch of novel disease modifying therapies and the flood of generic gabapentin products.
Scope of Report:
Quantitative treatment data from over 364 physicians from the US, Japan, France, Germany, Italy, Spain and the UK
Analysis of epidemiology, assessment and referral patterns, first- to third-line treatments, and unmet market needs
Discussion of the R&D drug pipeline for DNP, including analysis of ruboxistaurin, fidarestat, pregabalin, lamotrigine, and duloxetine
Coverage of the hot topics including the upcoming launch of pregabalin and disease modifying therapies
Report Highlights:
DNP patients are often referred to neurologists or pain specialists for treatment, where they are likely given gabapentin and/or amitriptyline. However, as these treatments often only provide marginal relief of DNP symptoms, there remains a need for improved long-term pain management.
With the launch of pregabalin in 2004, Pfizer will effectively retain much of its market share when gabapentin finally loses US patent protection. Approval for DNP in the US will be a major advantage in the increasingly competitive neuropathic pain market as currently there are no drugs licensed for this indication.
Over the coming years competition in the market will be fierce; therefore smaller companies will need to establish clear positioning versus major players, requiring significant investment.
Such smaller companies should consider alternative strategies to head-to-head DNP monotherapy competition.
Reasons to Purchase Report:
Forecast product sales by understanding key aspects of DNP epidemiology, diagnosis, and treatment
Gain a better understanding of the challenges faced by future players in the DNP market
Predict trends in the treatment of DNP and how to capitalize on forthcoming changes in treatment practice
Customers who bought this item also bought
Stakeholder Insight: Neuropathic Low Back Pain - Off-label Revenue Despite Diagnostic Challenge
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Neuropathic Pain Insight - Life Beyond Gabapentin
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
Postoperative Pain: Dynastat Cutting Up The Pain Market
Strategic Perspectives 2001: Neuropathic pain - Catch 22: high revenue potential but a high risk investment
Competitive Strategies in Pain Management, 2001 Edition
|
|
|
|
